Amarin acquires global license to novel nasal Lorazepam formulation
Amarin Corporation in the UK has acquired a global licence to develop and market a novel, nasal lorazepam formulation for the out-patient treatment of emergency seizures in epilepsy patients, specifically status epilepticus (SE) and acute repetitive seizures (ARS).
Amarin Corporation in the UK has acquired a global licence to develop and market a novel, nasal lorazepam formulation for the out-patient treatment of emergency seizures in epilepsy patients, specifically status epilepticus (SE) and acute repetitive seizures (ARS).
There are approximately 40,000 deaths in the US each year associated with such emergency seizures.
Rick Stewart, ceo of Amarin, said: The potential of this nasal lorazepam opportunity is significant in addressing this unmet medical need. We are very excited about this opportunity as it fits neatly into Amarin's neurology focused strategy.. This formulation uses patent protected NanoCrystal technology from Elan Corporation.
Diazepam rectal gel is the only treatment currently approved by the US FDA for seizure emergencies in the out-patient setting. Consequently, an opportunity exists for the development of a product with a more convenient route of administration permitting broader out-patient treatment of SE and ARS in both children and adults.